Olaplex Acquisition: Olaplex has acquired Purvala Bioscience, marking its first acquisition since the brand's inception over ten years ago.
Purvala Overview: Purvala is a Boston-based biotech company founded by Drs. Bradley Olsen and Justin Paloni, focusing on developing bioinspired technologies for health and beauty applications.
Innovative Focus: Since its establishment in 2020, Purvala has concentrated on creating high-performing molecules inspired by natural biological structures.
Leadership Background: Dr. Bradley Olsen, one of Purvala's founders, is also a Professor of Chemical Engineering at MIT.
OLPX
$1.43+Infinity%1D
Analyst Views on OLPX
Wall Street analysts forecast OLPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLPX is 1.99 USD with a low forecast of 1.25 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast OLPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLPX is 1.99 USD with a low forecast of 1.25 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
5 Hold
0 Sell
Moderate Buy
Current: 1.300
Low
1.25
Averages
1.99
High
4.00
Current: 1.300
Low
1.25
Averages
1.99
High
4.00
Morgan Stanley
Dara Mohsenian
Equal Weight
downgrade
2025-11-10
Reason
Morgan Stanley
Dara Mohsenian
Price Target
2025-11-10
downgrade
Equal Weight
Reason
Morgan Stanley analyst Dara Mohsenian lowered the firm's price target on Olaplex to $1.40 from $1.75 and keeps an Equal Weight rating on the shares.
Barclays
Equal Weight
downgrade
2025-11-10
Reason
Barclays
Price Target
2025-11-10
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Olaplex to $1.25 from $1.50 and keeps an Equal Weight rating on the shares post the earnings report. The firm says the company is nearly two years into a multi-year transformation.
Canaccord
Hold
to
Buy
upgrade
$2
2025-08-25
Reason
Canaccord
Price Target
$2
2025-08-25
upgrade
Hold
to
Buy
Reason
Canaccord upgraded Olaplex to Buy from Hold with a price target of $2, up from $1.50. The company has seen a brand "reinvigoration" and is set to return to growth, the analyst tells investors in a research note. The firm says that after over two years of normalization, Olaplex's brand is seeing sales and margins stabilize with an opportunity for more consistent growth as investments in marketing, merchandising, and innovation start to take hold. Canaccord finds the stock's valuation compelling at current levels.
Canaccord
Hold
downgrade
$2
2025-08-08
Reason
Canaccord
Price Target
$2
2025-08-08
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Olaplex Holdings to $1.50 from $2 and keeps a Hold rating on the shares. The firm said they reported Q2 results with sales turning positive for the first time in nine quarters but said they remain on the sidelines until they see more consistent positive results across the business.
About OLPX
Olaplex Holdings, Inc. is a foundational health and beauty company. Its Complete Bond Technology works by protecting, strengthening and relinking all three bonds during and after hair services. Its product portfolio includes 23 products that support the hair health needs of its professional hairstylist and consumer communities. It developed its patent-protected bond-building technology, Bis-amino, which works on the molecular level to repair the hair’s disulfide bonds. Leveraging its Bis-amino technology, its two-part salon and at home bond-building treatments are complete bond builders that can repair all three main chemical bonds deep inside the hair: hydrogen, ionic and disulfide bonds. Its OLAPLEX Bond Shaping Technology is a proprietary peptide that penetrates deep into the hair to strengthen, rebuild, and reform curl-shaping disulfide bonds. Its products are sold globally through an omnichannel model serving the professional, specialty retail, and direct-to-consumer channels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
